U.S. Markets closed

The Trendlines Group Ltd. (42T.SI)

SES - SES Delayed Price. Currency in SGD
Add to watchlist
0.0970+0.0010 (+1.04%)
At close: 5:04PM SGT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0960
Open0.0970
Bid0.0960 x 0
Ask0.0970 x 0
Day's Range0.0970 - 0.0980
52 Week Range0.0540 - 0.1380
Volume121,200
Avg. Volume511,117
Market Cap76.746M
Beta (5Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)-0.0040
Earnings DateAug 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Serial Healthcare Entrepreneur Amir Belson, M.D. Joins Ceretrieve as Chairman
    PR Newswire

    Serial Healthcare Entrepreneur Amir Belson, M.D. Joins Ceretrieve as Chairman

    Ceretrieve, a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY), a leading Israel- and Singapore-based investment group focused on high-growth medical and agrifood technologies, announced that it has appointed Amir Belson M.D. as chairman following the company's close of $1.5 million in funding.

  • Vvital Biomed Announces Stellar Advisory Board
    PR Newswire

    Vvital Biomed Announces Stellar Advisory Board

    Vvital Biomed ("Vvital"), a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY), a leading Israel- and Singapore-based investment group focused on high-growth medical and agrifood technologies, announced that three world-renowned cardiologists have recently joined the advisory board of Vvital, strengthening the company's capabilities to build its solution for mitral and tricuspid valve repair.

  • Limaca Medical Raises $1.25 Million to Enhance Precision Medicine Through Improved Biopsies
    PR Newswire

    Limaca Medical Raises $1.25 Million to Enhance Precision Medicine Through Improved Biopsies

    Limaca Medical, ("Limaca") a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY), a leading Israel- and Singapore-based investment group focused on high-growth medical and agrifood technologies, announced it has closed $1.25 million of a $1.5 million round to complete first-in-human ("FIH") procedures, post-market clinical studies, and obtain regulatory approvals.